Investigation of Neurophysiological Markers, Possibly Specific of Two Subforms of Psychotic Disorders

NCT03649581 | Recruiting

• 1 other identifier: 7058
• Study Type: interventional
• Target: 84
• Locations: 1 country
• Sites: 1

Brief Summary

The current diagnostic criteria for schizophrenia and other psychotic disorders are relatively broad and lack precision. Therefore, distinct diseases may be grouped together under the same diagnostic category, although these diseases may differ according to their clinical expression, prognosis and perhaps their physiopathological causes. We think that identifying subforms of psychotic disorders that are more homogeneous will better enable to understand their respective physiopathological causes and find personalized treatments. This study will compare two subforms of psychotic disorders that have been clinically distinguished in the 1970s. These phenotypes have however not been validated yet using scientific investigations. Using clinical assessments, cognitive evaluations and neurophysiological measures (fMRI) investigating the domains of affect and psychomotoricity , we expect that these two subforms will differ on their clinical, cognitive and neurophysiological characteristics, namely: hebephrenia will be associated with deficits on the affect markers , and respect psychomotoricity (catatonia scales, tests assessing movement planification) whereas the opposite pattern will be observed for periodic catatonia.

Conditions

Schizophrenia

Outcome Measures

Primary Outcomes (2)

• Index of affect

  Compare two groups of markers relating respectively to affectivity in two subforms of schizophrenia: periodic catatonia and hebephrenia in order to highlight a possible double dissociation

  6 months after inclusion

• Index of psychomotoricity

  Compare two groups of markers relating to psychomotricity in two subforms of schizophrenia: periodic catatonia and hebephrenia in order to highlight a possible double dissociation

  6 months after inclusion

Study Arms (3)

patient with schizophrenia and periodic catatonia

EXPERIMENTAL

Other: compare the two groups of schizophrenic patients; Other: compare the two groups of schizophrenic patients versus volunteers

patient with schizophrenia and hebephrenia

EXPERIMENTAL

Other: compare the two groups of schizophrenic patients; Other: compare the two groups of schizophrenic patients versus volunteers

healthy volunteers

ACTIVE COMPARATOR

Other: compare the two groups of schizophrenic patients; Other: compare the two groups of schizophrenic patients versus volunteers

Interventions

compare the two groups of schizophrenic patients OTHER

Compare two groups of markers relating respectively to psychomotricity and affectivity in two subforms of schizophrenia: periodic catatonia and hebephrenia in order to highlight a possible double dissociation: 1. abnormalities of markers related to affectivity in Hebephrenia (with preservation of these markers in periodic catatonia), 2. abnormalities of markers related to psychomotricity in periodic catatonia (with markers of these tests in Hebephrenia).

healthy volunteers; patient with schizophrenia and hebephrenia; patient with schizophrenia and periodic catatonia

compare the two groups of schizophrenic patients versus volunteers OTHER

compare the results of the schizophrenic patient group with healthy volunteers

healthy volunteers; patient with schizophrenia and hebephrenia; patient with schizophrenia and periodic catatonia

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• for both patients and controls
• male or female willing to participate and who have signed up the legal document
• under the protection of health insurance for patients only
• schizophrenia or schizo-affective disorder according to the DSM-5 criteria
• periodic catatonia or hebephrenia accordin to WKL classification
• clinically stable for at least 2 months
• in or out patients for controls only
• no psychiatric history

You may not qualify if:

• for both patients and controls
• current severe or unstable somatic illness
• neurological history (epilepsia, brain injury, brain surgery…)
• current substance use disorder (DSM-5)
• current major depressive disorder (DSM-5)
• mental retardation (IQ \< 70)
• pregnancy, breast feeding
• current legal control
• contra-indication for fMRI for controls only psychotropic intake during the last 3 weeks

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service de Psychiatrie I, Hôpital Civil, Hôpitaux Universitaires de Strasbourg

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

Schizophrenia

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders

Central Study Contacts

Fabrice BERNA, MD

CONTACT

03 88 11 64 62; fabrice.berna@chru-strasbourg.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 21, 2018
• First Posted: August 28, 2018
• Study Start: February 28, 2019
• Primary Completion (Estimated): February 2, 2027
• Study Completion (Estimated): February 2, 2027
• Last Updated: August 3, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)